A Phase 1 Multicenter, Dose-escalation Study of LY573636-Sodium in Combination With 1) Gemcitabine HCl or 2) Docetaxel or 3) Temozolomide or 4) Cisplatin, or 5) Erlotinib in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2016
At a glance
- Drugs Tasisulam (Primary) ; Cisplatin; Docetaxel; Erlotinib; Gemcitabine; Temozolomide
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 25 Aug 2016 Status changed from active, no longer recruiting to completed.
- 17 Jun 2015 Planned End Date changed from 1 Feb 2015 to 1 Feb 2016 as per ClinicalTrials.gov record.
- 30 Sep 2014 Planned End Date changed from 1 Dec 2013 to 1 Feb 2015, according to ClinicalTrials.gov record.